Navigation Links
Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009
Date:2/26/2009

lity services, the success of the Company's business model, improving case volumes, increasing revenues, customer adoption and growth, the Company's capacity to manage and support future growth and ability to expand its business, hire additional personnel and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects and ability to capture additional bone marrow market share in the U.S., estimated effective tax rates and the Company's financial guidance for 2009. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks, financial risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the full-year period ended December 31, 2008 and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

                            [Financial tables follow]



                                   GENOPTIX, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                      (in thousands, except per share data)

                                     Three Months En
'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
2. Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
3. Genoptix Announces the Addition of New Members to Board of Directors
4. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
5. Genoptix Reports Strong Financial Results for First Quarter 2008
6. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
7. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
8. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
9. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
10. Genoptix Announces Pricing of Secondary Public Offering
11. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 30, 2015 “In ... changing local and federal regulations, we provide education ... their patients who are suffering from pain, within ... Srinivas Nalamachu, MD, professor of rehabilitation medicine and ... in Overland Park, Kansas. , A new flight ...
(Date:5/29/2015)... What does community do? , According to a ... to plant gardens, to teach young people, to laugh, ... issues. Community invites everyone to help improve lives for ... Does" was commissioned by The Denver Foundation, the largest ... the foundation’s Annual Celebration in May. At just over ...
(Date:5/29/2015)... 2015 The third annual Newport 10 ... closed to new registration, starts outside the east wall ... competitive running event demonstrates the power of combining professional ... benefit – in this case, historic preservation. , ... famed Ocean Drive and passes by many Bellevue Avenue ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 According to a ... in 10 full-time workers has a substance abuse problem - ... more than 111,500 adults with full-time jobs, revealed that 9.5% ... the previous year. (1) The National Council on Alcoholism and ... per year, and an estimated 70% of the 14.8 million ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
... eye of now co-editor Rick Drake and colleagues at the ... now the highest ranking journal in science education? If ... correct! As AAA publisher Wiley-Blackwell put it in a ... as the number 1 ranked journal in Education, Scientific Disciplines." ...
... scientists at Duke University Medical Center and Johns Hopkins ... of drug therapy to treat the second most common ... been looking for the primary cancer genes involved in ... that held the probable mutations, but not the particular ...
... Summer for most people means time spent outdoors, which ... arthropod-borne diseases, such as "rickettsial diseases" infectious diseases ... fleas, ticks and mites. Now a $1.6 million ... enable an entomologist at the University of California, Riverside ...
... Southwestern Medical Center researchers may suggest new strategies for successful ... such as leukemia, lymphoma and myeloma. The study, published ... the first time that adult blood stem cells can be ... rejection. It also opens up further studies in stem cell ...
... and Zappos.com are famous for their "work hard, play ... employees healthier too? According to a Tel Aviv University ... health benefits. Dr. Sharon Toker of the ... School of Business Administration says that employees who believe ...
... By Ellin Holohan HealthDay Reporter , THURSDAY, ... antidepressants than ever before to deal with everyday stress, ... to patients with no mental health diagnosis, a new ... Lexapro are now the third most widely prescribed group ...
Cached Medicine News:Health News:AAA journal rockets to top of science education category 2Health News:Elusive gene mutations found for malignant brain tumor 2Health News:UC Riverside entomologist to study diseases transmitted by ticks 2Health News:UC Riverside entomologist to study diseases transmitted by ticks 3Health News:Hang out at the water cooler, live longer 2Health News:Hang out at the water cooler, live longer 3Health News:Americans' Use of Antidepressants On the Rise: Study 2Health News:Americans' Use of Antidepressants On the Rise: Study 3
(Date:5/29/2015)... VANCOUVER, British Columbia and ... DelMar Pharmaceuticals, Inc. (OTCQX: ... focused on developing and commercializing proven cancer therapies ... data at the American Association of Cancer ... on the potential for its lead product ...
(Date:5/29/2015)...  Eli Lilly and Company (NYSE: LLY ) ... they have entered into a clinical trial collaboration to ... anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ... medicine. The planned study will assess the combination as ... The Phase I study is expected to establish ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... UK pharma group GlaxoSmithKline reports a 2% ... underlying sales momentum. In an interview with ... CFO Simon Dingemans review Q2 results including overall delivery ... a review of the recently implemented Drug Performance Units. ...
... Pharmaceuticals, Inc. announced the following news today concerning the future ... On December 31, 2011, the FDA ban ... a propellant will become effective. Primatene® Mist has ... symptoms for over 40 years. The ban on the sale ...
Cached Medicine Technology:Statement on Availability of Primatene® Mist CFC 2
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... is a dedicated high performance ... applications. Genegnome completely automates the ... It provides superbly accurate results ... use, unique image analysis algorithms ...
... Chrono-log's wide range of Platelet ... capabilities to meet particular needs. Single, ... available, with chart recorder outputs or ... the Chrono-log Optical aggregometers, which measure ...
Medicine Products: